EXECUTIVE ENGAGEMENTS
OUTREACH
2273
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
409
Interactions with Platform & by Email
PARTICIPANTS
68
Unique # Participated
VALIDATIONS
31
Responses Validated*
COMPETITORS
25
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
18
PAGES
73
EDITION
18
PRICE
USD $5450
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Anti-Obesity Drugs estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at a CAGR of 19.4% over the period 2020-2027.
The Anti-Obesity Drugs market in the U.S. is estimated at US$443.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$903.4 Million by the year 2027 trailing a CAGR of 19% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.2% and 16.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.
SELECT PLAYERS
Eisai Co. Ltd. (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc; Novo Nordisk A/S (Denmark); Rhythm Pharmaceuticals (US); VIVUS Inc. (US)
SEGMENTS
» Segment (Anti-Obesity Drugs)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Obesity and Overweight Statistics |
| Recent Market Activity |
| Obesity - A Prelude |
| Anti-Obesity Drugs: A Market Characterized by High Unmet Needs |
| Currently Available Anti-Obesity Medications |
| Select Currently Available Short-term and Long-term Anti-Obesity Medication |
| Select Off-Label Drugs for Obesity |
| Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth |
| Semaglutide: Highest Potential in the AOM Pipeline |
| Setbacks of Past Drugs |
| Positive Road Ahead for Belviq |
| Relaunch of Xenical |
| Relaunch of Contrave® |
| Reluctance among Patients, Physicians, and Payers Hurts Market Prospects |
| New Drug Development - High on the Agenda, Despite the Market Restraints |
| Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018 |
| Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018 |
| Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018 |
| Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space |
| Competitive Landscape |
| Novo Nordisk - The Leading Player in the Market |
| The United States - The Largest Obesity and Anti-Obesity Market |
| Europe - A Market with Vast Potential |
| Obesity Creeps Up in Developing Countries |
| 2. FOCUS ON SELECT PLAYERS |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| GlaxoSmithKline Plc. (UK) |
| Eisai Co., Ltd. (Japan) |
| Novo Nordisk A/S (Denmark) |
| Rhythm Pharmaceuticals (USA) |
| VIVUS, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Alarming Rise in Global Obesity Levels - The Major Growth Factor |
| Classification of BMI |
| Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion |
| Growing Middle Class Population to Drive the Market Growth |
| Childhood Obesity - A Market with Unmet Needs |
| Commercial Weight-Loss Companies Foray into the Market |
| Online Drug Stores Boost Sales |
| Barriers to Development of Effective Drugs |
| Regulatory Additions - A Barrier to Entry? |
| High Drug Development Costs - A Major Setback |
| Weight Loss Alternatives - A Market Dampener |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| CANADA |
| Canada Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| JAPAN |
| Japan Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| CHINA |
| China Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| EUROPE |
| Europe Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| GERMANY |
| Germany Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| ITALY |
| Italy Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UNITED KINGDOM |
| UK Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| IV. COMPETITION |
| Total Companies Profiled: 25 |
China Has Risen Into An Economic Powerhouse.
Find Out How You Can Leverage This Opportunity!
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com